Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a first wireless communication device (WCD) may receive, from a second WCD, transmission configuration indicator (TCI) state information that defines a set of TCI state configurations for a full duplex operation, wherein TCI state configurations of the set of TCI state configurations are associated with respective receive beams and respective transmit beams. The WCD may transmit, to the second WCD, an indication of one or more candidate TCI states, associated with the set of TCI state configurations, for selection by the second WCD for communications using the full duplex operation. Numerous other aspects are provided.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a base station, at least one of a first indication of a set of beams allowed for sidelink communication or a second indication of a range allowed for a sidelink transmission parameter. The UE may communicate on a sidelink in accordance with at least one of the set of beams or the range. Numerous other aspects are described.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may perform a physical layer measurement on a non-serving cell of the UE. The UE may report a measurement value of the physical layer measurement to a serving cell of the UE based at least in part on the physical layer measurement satisfying a threshold. The UE may receive, based at least in part on reporting the physical layer measurement, a physical layer reference signal measurement configuration for the non-serving cell. The UE may transmit a measurement report based at least in part on the physical layer reference signal measurement configuration. Numerous other aspects are provided.

Abstract: Techniques manage log data. Such techniques involve receiving log data describing a state of an application system at a target time point. Such techniques further involve determining whether a level of the log data satisfies a predetermined level. Such techniques further involve, in response to determining that the level of the log data satisfies the predetermined level, storing log data within a predetermined range adjacent to the target time point to a log repository of the application system, the predetermined range indicating the amount of log data expected to be stored.

Abstract: A method for manufacturing a semiconductor structure includes the following operations. A support layer and a first dielectric layer that are stacked are formed on the substrate, in which first trenches are formed in the support layer and the first dielectric layer. A first blocking layer covering sidewalls and bottoms of the first trenches and a top surface of the first dielectric layer is formed. The first blocking layer and the first dielectric layer are etched to form etching holes. The first dielectric layer exposed by the etching holes is removed to form cavities. A second blocking layer is formed, which seals the etching holes at the tops of the cavity. Part of the first blocking layer in the first trenches is removed so that the first trenches expose the substrate. Wires are formed in the first trenches.

Abstract: The disclosure provides a semiconductor structure and a method for manufacturing a semiconductor structure, relates to the field of semiconductor manufacturing technologies. The semiconductor structure includes: a substrate, having a bit line groove; a bit line, located in the bit line groove, and extending in a first direction; and a vertical transistor, located on the bit line. The bit line includes a bit line contact structure, and the bit line contact structure is a concave structure and/or a convex structure. The vertical transistor is electrically connected to the bit line by the bit line contact structure.

Abstract: A communication method and apparatus relating to the field of communication technologies. The method includes a network device receives at least two packets, and aggregates the at least two packets to obtain aggregated packets. Messages to which the at least two packets separately belong have a same message index. The message index is used to index the messages to which the at least two packets separately belong. In the communication method provided in this application, the network device is used to implement aggregation processing, to reduce a communication delay and data redundancy in a communication network.

Abstract: The present application provides a semiconductor structure and a preparation method thereof, including: a substrate; a trench; a bit line contact structure; a bit line structure; a bit line protection structure, the bit line protection structure including a top dielectric layer and a sidewall structure, the top dielectric layer is located on the bit line structure and forms a laminated structure together with the bit line structure; the sidewall structure covers part of sidewalls of the laminated structure on the substrate, the sidewall structure has a first air gap; an isolation pattern structure, the isolation pattern structure has a second air gap, the isolation pattern structure extends along a second direction, the second direction intersects with the first direction, to form capacitance contact hole between the adjacent bit line protection structures and the adjacent isolation pattern structures.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: An electronic guide dog includes: a main frame, front drive wheels disposed on both sides of a front portion of the main frame, and rear drive wheels disposed on both sides of a rear portion of the main frame, wherein the front drive wheels and the rear drive wheels are connected to the main frame through front arms and rear arms, respectively; wherein the electronic guide dog further comprises: a head frame hinged to a front of a top end of the main frame, wherein a signal receiving board is provided on the head frame; a drive mechanism comprising a rear drive motor; a swivel obstacle avoidance mechanism comprising an infrared sensor provided on a front side of the main frame, a left front drive motor and a right front drive motor; an identification braking mechanism; a front arm swing mechanism; and an auxiliary support mechanism.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: An electronic guide dog includes: a main frame, front drive wheels disposed on both sides of a front portion of the main frame, and rear drive wheels disposed on both sides of a rear portion of the main frame, wherein the front drive wheels and the rear drive wheels are connected to the main frame through front arms and rear arms, respectively; wherein the electronic guide dog further comprises: a head frame hinged to a front of a top end of the main frame, wherein a signal receiving board is provided on the head frame; a drive mechanism comprising a rear drive motor; a swivel obstacle avoidance mechanism comprising an infrared sensor provided on a front side of the main frame, a left front drive motor and a right front drive motor; an identification braking mechanism; a front arm swing mechanism; and an auxiliary support mechanism.

Abstract: The present invention provides Hsp90 drug conjugates (HDCs) comprising an Hsp90 ligand or prodrug thereof, a linker moiety and a payload moiety. The invention also provides methods for treating a disease or disorder in a subject, for example cancer, with an HDC.

Abstract: A method, computer program product, and computing system for receiving a plurality of requests to store at least one data object in a storage array. A ranking of a plurality of data object types in order of significance may be received. One or more data objects of a plurality of data objects may be removed from the storage array based upon, at least in part, the ranking of the one or more data object types of a plurality of data object types associated with the one or more data objects of the plurality of data objects. The at least one data object may be stored in the storage array.

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Abstract: The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, X1, X2, Z, R3, R4, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.